Moleculin Biotech, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Moleculin Biotech, Inc. (MBRX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$580.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-21
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$1.47M.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$3.12M.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$1.39M, a 456.01% decline year-over-year.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $5.40M, a 39.39% increase year-over-year.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$580.00K, a 121.43% decline from fiscal 2017.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $2.71M, a 45.63% decline from fiscal 2016.
- Moleculin Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $4.98M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 2 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 5 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$4.59M derived: sum of 2 quarters · filed 2019-02-21 | -$5.98M derived: sum of 3 quarters · filed 2019-02-21 | -$580.00K 10-K · filed 2019-02-21 | ||||||
| 2018-09-30 | -$3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$4.51M derived: sum of 2 quarters · filed 2018-11-13 | $886.00K 10-Q · filed 2018-11-13 | -$136.00K derived: sum of 4 quarters · filed 2019-02-21 | ||||||
| 2018-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $4.01M 10-Q · filed 2018-08-10 | $2.99M derived: sum of 3 quarters · filed 2019-02-21 | $2.45M derived: sum of 4 quarters · filed 2019-02-21 | ||||||
| 2018-03-31 | $5.40M 10-Q · filed 2018-05-14 | $4.38M derived: sum of 2 quarters · filed 2019-02-21 | $3.84M derived: sum of 3 quarters · filed 2019-02-21 | $4.23M derived: sum of 4 quarters · filed 2019-02-21 | ||||||
| 2017-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$1.56M derived: sum of 2 quarters · filed 2019-02-21 | -$1.17M derived: sum of 3 quarters · filed 2019-02-21 | $2.71M 10-K · filed 2019-02-21 | ||||||
| 2017-09-30 | -$536.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$145.00K derived: sum of 2 quarters · filed 2018-11-13 | $3.73M 10-Q · filed 2018-11-13 | $2.55M derived: sum of 4 quarters · filed 2018-11-13 | ||||||
| 2017-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $4.26M 10-Q · filed 2018-08-10 | $3.09M derived: sum of 3 quarters · filed 2018-08-10 | $2.03M derived: sum of 4 quarters · filed 2018-08-10 | ||||||
| 2017-03-31 | $3.87M 10-Q · filed 2018-05-14 | $2.70M derived: sum of 2 quarters · filed 2018-05-14 | $1.64M derived: sum of 3 quarters · filed 2018-05-14 | $8.62M derived: sum of 4 quarters · filed 2018-05-14 | ||||||
| 2016-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | -$2.24M derived: sum of 2 quarters · filed 2018-03-28 | $4.75M derived: sum of 3 quarters · filed 2018-03-28 | $4.98M 10-K · filed 2018-03-28 | $4.98M 10-K · filed 2017-04-03 | |||||
| 2016-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $5.92M derived: sum of 2 quarters · filed 2017-11-13 | $6.16M 10-Q · filed 2017-11-13 | $6.16M 10-Q · filed 2016-11-21 | ||||||
| 2016-06-30 | $6.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $7.22M 10-Q · filed 2017-08-11 | $7.22M 10-Q · filed 2016-08-15 | |||||||
| 2016-03-31 | $232.00K 10-Q · filed 2017-05-12 | $231.57K 10-Q · filed 2016-06-16 | ||||||||
| 2015-12-31 | $28.09K 10-K · filed 2017-04-03 | |||||||||
| 2015-09-30 | $87.34K 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |